08/02/2021
The Prostate Cancer Foundation Applauds the Introduction of H.R.4880 – Veteran’s Prostate Cancer Treatment and Research Act
We thank champions Congressman Neal Dunn, M.D. (FL-02) and Congresswoman Elissa Slotkin (MI-08) for the recent introduction of the Veteran’s Prostate Cancer Treatment and Research Act (H.R. 4880). Since 2016, PCF has been raising awareness and administering $50 million in funding to tackle prostate cancer as the number one cancer. Read More
07/12/2021
Targeting PSMA: Serious Side Effects, and Navigating a Safe Course (Part 4)
EFFORTS TO REDUCE SIDE EFFECTS So, with all this published success, is there a downside to radioligands? Just like the use of magic in fairy tales – they come with a price. The radioligands target the salivary glands, where there is a small amount of PSMA produced. Beta particles such. Read More
07/01/2021
Targeting PSMA: Dramatic Success (Part 3)
PCF-funded investigator Neil Bander, M.D., Director of Urological Oncology Research at Weill Cornell and a pioneer in the study of PSMA (prostate-specific membrane antigen), developed an antibody that targets this molecule that sits on the surface of prostate cancer cells. He later characterized PSMA, and found many reasons why it. Read More
06/16/2021
Screening and Family Risk
Get screened Prostate cancer screening starts with a simple blood test, called a PSA test. PSA stands for prostate specific antigen. When should you be screened? It depends on a few risk factors. Start to talk with your doctor about prostate cancer screening when you are age 40 if you. Read More
Jerk Kebabs
Download the recipe card Jerk Kebabs Recipe courtesy of Beth Ginsberg Number of servings: 8 Prep time: 30 minutes (plus marinating time) Cook time: 10 minutes Safety Note: Habanero peppers are extremely hot. Be careful when handling them not to touch your eyes or other sensitive areas. Ingredients: Jerk Marinade. Read More
06/10/2021
Targeting PSMA: Making it Happen (Part 2)
PCF-funded investigator Neil Bander, M.D., Director of Urological Oncology Research at Weill Cornell and a pioneer in the study of PSMA, saw the potential of targeting PSMA, a molecule that sits on the surface of prostate cancer cells, soon after it was discovered more than 30 years ago. His PCF-funded. Read More
05/27/2021
PyL PSMA PET Imaging: Shining the Spotlight on Tiny Bits of Cancer
Maybe you’ve been diagnosed with high-risk prostate cancer. Maybe you have already been treated for prostate cancer, but your PSA is starting to creep back up, which means that the treatment didn’t get all of the cancer – but maybe it’s just right there in the prostate area, easily targetable. Read More
05/17/2021
Millions of Cancer Screenings Missed During the Pandemic
When the U.S. suddenly went into lockdown in March of 2020, the delivery of health care was drastically changed. To protect patients and staff from exposure, to conserve valuable PPE, and, for some hospitals, to focus on caring for COVID patients, hospitals and clinics reduced non-emergency care. Prostate cancer screening. Read More
05/17/2021
Targeting PSMA: Amazing Potential (Part 1)
Nearly three decades ago, Neil Bander, M.D., now Director of Urological Oncology Research at Weill Cornell, saw the potential of a newly discovered molecule called PSMA to be used in two ways: for imaging and also for precisely targeted treatment of prostate cancer. Over the last few years, both aspects. Read More
05/11/2021
“Taking it to the next level:” Walking into remission
Need a reason to take PCF’s Go the Distance: 100 Miles in June challenge? Read one man’s story – then join us here. When Dick Cozza, now 76, was diagnosed with metastatic prostate cancer over 18 months ago, he says his doctors were astonished. “They told me they’d never seen. Read More